Little Green Pharma (ASX:LGP) said the 12-month follow-up results of the Quality of Life Evaluation Study (QUEST) initiative, showed clinically meaningful improvements across all patients for health-related quality of life, fatigue, and sleep, as well as clinically meaningful reductions in anxiety, pain, depression and sleep disorders in patients, according to a Friday Australian bourse filing.

The study is investigating the effect of medicinal cannabis on patient quality of life and chronic conditions. The firm exclusively supplied the medicinal cannabis products in the study.

The University of Sydney led the study. The 12-month findings have been peer-reviewed and published in the open-access journal, PLOS One.

The next phase of the initiative is a global study led by Curtin University, which is recruiting patients.

Study participants were aged between 18 and 97 years, and 63% of them were female. Chronic musculoskeletal pain and chronic neuropathic pain at 63%, sleep disorders at 23%, and generalized anxiety disorder and depression at 11% were the most reported conditions.

The participants in the study used oral medicinal cannabis according to the study protocol and had previously experienced unsuccessful results with other pharmaceutical treatments.